Library Subscription: Guest
Critical Reviews™ in Oncogenesis

Published 4 issues per year

ISSN Print: 0893-9675

ISSN Online: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

The Involvement of Bcr in Leukemias with the Philadelphia Chromosome

Volume 9, Issue 1, 1998, pp. 1-18
DOI: 10.1615/CritRevOncog.v9.i1.10
Get accessGet access

ABSTRACT

In this review, the role of Bcr sequences within Bcr-Abl and the role of the Bcr protein itself in leukemias with the Philadelphia chromosome are discussed. An overview of the oncogenic effects of Bcr-Abl is presented together with Bcr-Abl's effects on several signal transduction pathways. Bcr sequences within Bcr-Abl are known to have an important function in transducing Bcr-Abl's oncogenic signal, yet the role of the Bcr protein encoded by the normal allele is not known. However, several recent findings suggest that Bcr is a conditional negative regulator of Bcr-Abl. From these findings, my colleagues and I have developed a molecular model of the early stage (benign phase) of chronic myelogenous leukemia in which the Bcr protein antagonizes the oncogenic effects of Bcr-Abl.

CITED BY
  1. Butturini Anna, Arlinghaus Ralph B., Gale Robert Peter, BCR/ABL, in Encyclopedia of Cancer, 2002. Crossref

  2. Charest Alain, Lane Keara, McMahon Kevin, Park Julie, Preisinger Elizabeth, Conroy Helen, Housman David, Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21), Genes, Chromosomes and Cancer, 37, 1, 2003. Crossref

  3. Kardinal Christian, Konkol Birgit, Schulz Axel, Posern Guido, Lin Hui, Adermann Knut, Eulitz Manfred, Estrov Zeev, Talpaz Moshe, Arlinghaus Ralph B., Feller Stephan M., Cell‐penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients, The FASEB Journal, 14, 11, 2000. Crossref

  4. Feller Stephan M., Tuchscherer Gabriele, Voss Jan, High Affinity Molecules Disrupting GRB2 Protein Complexes as a Therapeutic Strategy for Chronic Myelogenous Leukaemia, Leukemia & Lymphoma, 44, 3, 2003. Crossref

  5. Grunberger Thomas, Demin Peter, Rounova Olga, Sharfe Nigel, Cimpean Lorand, Dadi Harjit, Freywald Andrew, Estrov Zeev, Roifman Chaim M., Inhibition of acute lymphoblastic and myeloid leukemias by a novel kinase inhibitor, Blood, 102, 12, 2003. Crossref

  6. Arlinghaus Ralph, Sun Tong, Signal Transduction Pathways in BCR-ABL Transformed Cells, in Molecular Targeting and Signal Transduction, 119, 2004. Crossref

  7. Zhang Zhuo, Li Mao, Rayburn Elizabeth R, Hill Donald L, Zhang Ruiwen, Wang Hui, Oncogenes as Novel Targets for Cancer Therapy (Part I), American Journal of PharmacoGenomics, 5, 3, 2005. Crossref

  8. Kardinal Christian, Konkol Birgit, Lin Hui, Eulitz Manfred, Schmidt Enrico K., Estrov Zeev, Talpaz Moshe, Arlinghaus Ralph B., Feller Stephan M., Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes, Blood, 98, 6, 2001. Crossref

  9. Hamid Abdulaziz B., Petreaca Ruben C., Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells, Cancers, 12, 4, 2020. Crossref

  10. Arlinghaus Ralph B, Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia, Oncogene, 21, 56, 2002. Crossref

  11. Lin Feng, Monaco Giuseppe, Sun Tong, Liu Jiaxin, Lin Hui, Stephens Clifton, Belmont John, Arlinghaus Ralph B, BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model, Oncogene, 20, 15, 2001. Crossref

  12. Muvarak Nidal, Kelley Shannon, Robert Carine, Baer Maria R., Perrotti Danilo, Gambacorti-Passerini Carlo, Civin Curt, Scheibner Kara, Rassool Feyruz V., c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase–Activated Leukemias, Molecular Cancer Research, 13, 4, 2015. Crossref

Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections Prices and Subscription Policies Begell House Contact Us Language English 中文 Русский Português German French Spain